{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:48Z","timestamp":1784127648189,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-15447"],"award-info":[{"award-number":["MOP-15447"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-148884"],"award-info":[{"award-number":["PJT-148884"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.humimm.2019.04.009","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T08:46:21Z","timestamp":1556095581000},"page":"608-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Injury derived autoimmunity: Anti-perlecan\/LG3 antibodies in transplantation"],"prefix":"10.1016","volume":"80","author":[{"given":"M\u00e9lanie","family":"Dieud\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lo\u00efse","family":"Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jos\u00e9e","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.humimm.2019.04.009_b0005","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nri3607","article-title":"Apoptotic cell clearance: basic biology and therapeutic potential","volume":"14","author":"Poon","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2019.04.009_b0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ajt.12168","article-title":"Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury","volume":"13","author":"Cardinal","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.humimm.2019.04.009_b0015","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1073\/pnas.0900563106","article-title":"Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and \u201cantibodyome\u201d measures","volume":"106","author":"Li","year":"2009","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.humimm.2019.04.009_b0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1681\/ASN.2011060596","article-title":"Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury","volume":"23","author":"Sigdel","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.humimm.2019.04.009_b0025","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/ajt.12763","article-title":"Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss","volume":"14","author":"Gao","year":"2014","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.humimm.2019.04.009_b0030","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2353\/ajpath.2007.060728","article-title":"Autoantibodies to vimentin cause accelerated rejection of cardiac allografts","volume":"170","author":"Mahesh","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"40","key":"10.1016\/j.humimm.2019.04.009_b0035","doi-asserted-by":"crossref","first-page":"27220","DOI":"10.1074\/jbc.M801164200","article-title":"Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis","volume":"283","author":"Cailhier","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1096\/fj.03-0573fje","article-title":"Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on VSMC","volume":"18","author":"Raymond","year":"2004","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jlb.65.2.137","article-title":"The cell biology of leukocyte-mediated proteolysis","volume":"65","author":"Owen","year":"1999","journal-title":"J. Leukoc. Biol."},{"issue":"17","key":"10.1016\/j.humimm.2019.04.009_b0050","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1074\/jbc.271.17.10079","article-title":"The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases","volume":"271","author":"Whitelock","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.matbio.2009.09.005","article-title":"Myeloperoxidase-derived oxidants selectively disrupt the protein core of the heparan sulfate proteoglycan perlecan","volume":"29","author":"Rees","year":"2010","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1161\/CIRCRESAHA.111.250431","article-title":"The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection","volume":"110","author":"Soulez","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.humimm.2019.04.009_b0065","doi-asserted-by":"crossref","unstructured":"M. Soulez, E.A. Pilon, M. Dieude, et al., The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection, Circ Res., 110(1), 94\u2013104.","DOI":"10.1161\/CIRCRESAHA.111.250431"},{"key":"10.1016\/j.humimm.2019.04.009_b0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/prca.200780137","article-title":"Urinary proteomic analysis of chronic allograft nephropathy","volume":"2","author":"O'Riordan","year":"2008","journal-title":"Proteomics Clin. Appl."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pmic.201200267","article-title":"LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy","volume":"13","author":"Surin","year":"2013","journal-title":"Proteomics"},{"issue":"10","key":"10.1016\/j.humimm.2019.04.009_b0080","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/bmm.14.90","article-title":"The identification of three novel biomarkers of major adverse kidney events","volume":"8","author":"Haase","year":"2014","journal-title":"Biomarkers Med."},{"issue":"318","key":"10.1016\/j.humimm.2019.04.009_b0085","doi-asserted-by":"crossref","first-page":"318ra200","DOI":"10.1126\/scitranslmed.aac9816","article-title":"The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection","volume":"7","author":"Dieude","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.humimm.2019.04.009_b0090","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/CVI.00187-08","article-title":"Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus","volume":"15","author":"Majetschak","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"issue":"12","key":"10.1016\/j.humimm.2019.04.009_b0095","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1600-0625.2010.01151.x","article-title":"Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma","volume":"19","author":"Henry","year":"2010","journal-title":"Exp. Dermatol."},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/gut.2008.157016","article-title":"Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis","volume":"58","author":"Henry","year":"2009","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.humimm.2019.04.009_b0105","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0110","first-page":"215","article-title":"Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance","volume":"121","author":"Wada","year":"1993","journal-title":"J. Lab. Clin. Med."},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2010.10.014","article-title":"The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer","volume":"120","author":"Heubner","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.humimm.2019.04.009_b0120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbadis.2008.06.005","article-title":"Extracellular, circulating proteasomes and ubiquitin \u2013 incidence and relevance","volume":"1782","author":"Sixt","year":"2008","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/ndt\/gfl619","article-title":"Uraemic plasma decreases the expression of ABCA1, ABCG1 and cell-cycle genes in human coronary arterial endothelial cells","volume":"22","author":"Cardinal","year":"2007","journal-title":"Nephrol. Dialysis Transplant."},{"issue":"12","key":"10.1016\/j.humimm.2019.04.009_b0130","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1111\/ajt.13866","article-title":"Anti-LG3 antibodies aggravate renal ischemia-reperfusion injury and long-term renal allograft dysfunction","volume":"16","author":"Yang","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-6143.2005.00690.x","article-title":"Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy","volume":"5","author":"Joosten","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2019.04.009_b0140","doi-asserted-by":"crossref","unstructured":"Q. Zhang, E.F. Reed, Non-MHC antigenic targets of the humoral immune response in transplantation, Curr. Opin. Immunol., 22(5), 682\u2013688.","DOI":"10.1016\/j.coi.2010.08.009"},{"issue":"8","key":"10.1016\/j.humimm.2019.04.009_b0145","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181889748","article-title":"Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation","volume":"86","author":"Dragun","year":"2008","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.humimm.2019.04.009_b0150","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0002-9440(10)62557-6","article-title":"Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat","volume":"160","author":"Joosten","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.humimm.2019.04.009_b0155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/ajt.15082","article-title":"New insights into immune mechanisms of antiperlecan\/LG3 antibody production: importance of T cells and innate B1 cells","volume":"19","author":"Padet","year":"2019","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.humimm.2019.04.009_b0160","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.177.5.2749","article-title":"B-1 B cell development","volume":"177","author":"Hardy","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2019.04.009_b0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cimid.2017.08.002","article-title":"Development, phenotype, and function of non-conventional B cells","volume":"54","author":"Prieto","year":"2017","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.humimm.2019.04.009_b0170","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.coi.2006.07.010","article-title":"B-1 B cells: development, selection, natural autoantibody and leukemia","volume":"18","author":"Hardy","year":"2006","journal-title":"Curr. Opin. Immunol."},{"issue":"9","key":"10.1016\/j.humimm.2019.04.009_b0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.it.2006.07.005","article-title":"New perspectives in B-1 B cell development and function","volume":"27","author":"Montecino-Rodriguez","year":"2006","journal-title":"Trends Immunol."},{"issue":"9","key":"10.1016\/j.humimm.2019.04.009_b0180","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.4049\/jimmunol.0803980","article-title":"Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury","volume":"182","author":"Kulik","year":"2009","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2019.04.009_b0185","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2005-12-006858","article-title":"Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance","volume":"108","author":"Qian","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.humimm.2019.04.009_b0190","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.4049\/jimmunol.170.12.6151","article-title":"The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells","volume":"170","author":"Shaw","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2901","article-title":"The double life of a B-1 cell: self-reactivity selects for protective effector functions","volume":"11","author":"Baumgarth","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"41","key":"10.1016\/j.humimm.2019.04.009_b0200","doi-asserted-by":"crossref","first-page":"30383","DOI":"10.1074\/jbc.M606412200","article-title":"Perlecan proteolysis induces an alpha2beta1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation","volume":"281","author":"Laplante","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.humimm.2019.04.009_b0205","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1111\/j.1600-6143.2012.04053.x","article-title":"Expansion of polyreactive B cells cross-reactive to HLA and self in the blood of a patient with kidney graft rejection","volume":"12","author":"Porcheray","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"10","key":"10.1016\/j.humimm.2019.04.009_b0210","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/ajt.12394","article-title":"Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement","volume":"13","author":"Porcheray","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0215","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1681\/ASN.2017111157","article-title":"Post-transplant natural antibodies associate with kidney allograft injury and reduced long-term survival","volume":"29","author":"See","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.humimm.2019.04.009_b0220","article-title":"New insights into immune mechanisms of antiperlecan\/LG3 antibody production: importance of T cells and innate B1 cells","author":"Padet","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.humimm.2019.04.009_b0225","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1525-139X.2002.00083.x","article-title":"Inflammation in end-stage renal disease: sources, consequences, and therapy","volume":"15","author":"Stenvinkel","year":"2002","journal-title":"Semin. Dial."},{"issue":"12 Suppl. 3","key":"10.1016\/j.humimm.2019.04.009_b0230","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1681\/ASN.2006080926","article-title":"Inflammatory syndrome in patients on hemodialysis","volume":"17","author":"Jofre","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1\u20133","key":"10.1016\/j.humimm.2019.04.009_b0235","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000368940","article-title":"Update on inflammation in chronic kidney disease","volume":"39","author":"Akchurin","year":"2015","journal-title":"Blood Purif."},{"issue":"7","key":"10.1016\/j.humimm.2019.04.009_b0240","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.autrev.2016.03.005","article-title":"Vascular hypothesis revisited: role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis","volume":"15","author":"Cabral-Marques","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.humimm.2019.04.009_b0245","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/ajt.12397","article-title":"Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss","volume":"13","author":"Giral","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.TP.0000443224.66960.37","article-title":"Role of anti-vimentin antibodies in renal transplantation","volume":"98","author":"Besarani","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1432-2277.2012.01578.x","article-title":"Soluble CD30 correlates with clinical but not subclinical renal allograft rejection","volume":"26","author":"Hirt-Minkowski","year":"2013","journal-title":"Transpl. Int."},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0260","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00007890-200003270-00017","article-title":"Impact of the Banff '97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation","volume":"69","author":"Mueller","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0265","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1600-6143.2009.02938.x","article-title":"Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring","volume":"10","author":"Sis","year":"2010","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.humimm.2019.04.009_b0270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MNH.0b013e3283520efa","article-title":"Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum","volume":"21","author":"Haas","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"3","key":"10.1016\/j.humimm.2019.04.009_b0275","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ajt.12592","article-title":"Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy","volume":"14","author":"Angaswamy","year":"2014","journal-title":"Am. J. Transplant."},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0280","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection","volume":"352","author":"Dragun","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0285","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2249.2001.01654.x","article-title":"Screening of a HUVEC cDNA library with transplant-associated coronary artery disease sera identifies RPL7 as a candidate autoantigen associated with this disease","volume":"126","author":"Linke","year":"2001","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.humimm.2019.04.009_b0290","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/TP.0b013e3181d72091","article-title":"Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses","volume":"89","author":"Porcheray","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0295","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.4049\/jimmunol.1004195","article-title":"Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients","volume":"187","author":"Kalache","year":"2011","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2019.04.009_b0300","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.athoracsur.2010.06.009","article-title":"Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection","volume":"90","author":"Bharat","year":"2010","journal-title":"Ann. Thoracic Surgery"},{"issue":"7","key":"10.1016\/j.humimm.2019.04.009_b0305","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/00007890-200104150-00011","article-title":"Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation","volume":"71","author":"Jurcevic","year":"2001","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.humimm.2019.04.009_b0310","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1053-2498(03)00114-1","article-title":"Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome","volume":"23","author":"Morgun","year":"2004","journal-title":"J. Heart Lung Transplant."},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0315","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ki.2010.437","article-title":"De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection","volume":"79","author":"Sun","year":"2011","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0320","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1523-1755.2005.00085.x","article-title":"Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy","volume":"67","author":"Ishii","year":"2005","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.humimm.2019.04.009_b0325","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/j.1600-6143.2005.01102.x","article-title":"Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts","volume":"5","author":"Liptak","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2019.04.009_b0330","article-title":"Anti-perlecan antibodies and acute humoral rejection in hypersensitized patients without forbidden HLA specificities after kidney transplantation","author":"Riesco","year":"2018","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.humimm.2019.04.009_b0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.humimm.2019.04.009_b0340","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cei.12604","article-title":"Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells","volume":"180","author":"De Bruyne","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"Suppl. 9","key":"10.1016\/j.humimm.2019.04.009_b0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-6135.2004.00397.x","article-title":"Immunosuppression: practice and trends","volume":"4","author":"Kaufman","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"2 Suppl.","key":"10.1016\/j.humimm.2019.04.009_b0350","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.humimm.2019.04.009_b0355","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ki.2011.502","article-title":"Proteasome inhibitor-based therapy for antibody-mediated rejection","volume":"81","author":"Walsh","year":"2012","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.humimm.2019.04.009_b0360","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/TP.0b013e3182911739","article-title":"Proteasome inhibition profoundly affects activated human B cells","volume":"95","author":"Mulder","year":"2013","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.humimm.2019.04.009_b0365","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1432-2277.2011.01232.x","article-title":"Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death","volume":"24","author":"Treckmann","year":"2011","journal-title":"Transpl. Int."},{"issue":"1","key":"10.1016\/j.humimm.2019.04.009_b0370","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa0802289","article-title":"Machine perfusion or cold storage in deceased-donor kidney transplantation","volume":"360","author":"Moers","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.humimm.2019.04.009_b0375","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.humimm.2016.08.009","article-title":"Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan","volume":"77","author":"Carroll","year":"2016","journal-title":"Hum. Immunol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888591930148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888591930148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:51:15Z","timestamp":1759319475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019888591930148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S019888591930148X"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2019.04.009","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Injury derived autoimmunity: Anti-perlecan\/LG3 antibodies in transplantation","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2019.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}]}}